Despite clinical evidence and recommendations from international treatment guidelines, the use of perioperative chemotherapy for muscle-invasive bladder cancer in routine practice remains low.
Although multiple studies have described underutilization, there is an urgent need to better understand the elements contributing to the observed gaps in care. In this commentary, we explore what is known about the factors contributing to underutilization of perioperative chemotherapy for muscle-invasive bladder cancer. We also propose a framework to guide future knowledge translation activities in an effort to improve the care and outcomes of patients with this disease.
Written by:
Patafio FM, Mackillop WJ, Feldman-Stewart D, Robert Siemens D, Booth CM. Are you the author?
Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
Reference: Urol Oncol. 2014 Feb 6. pii: S1078-1439(13)00465-1.
doi: 10.1016/j.urolonc.2013.11.003
PubMed Abstract
PMID: 24508282
UroToday.com Bladder Cancer Section
